Literature DB >> 7575702

Lack of detection of enteroviral RNA or bacterial DNA in magnetic resonance imaging-directed muscle biopsies from twenty children with active untreated juvenile dermatomyositis.

L M Pachman1, D L Litt, A H Rowley, J R Hayford, J Caliendo, S Heller, B S Ticho, M Christensen, B Patterson, S R Ytterberg.   

Abstract

OBJECTIVE: To investigate for the presence of increased titers of circulating antibody to putative infectious agents and for detectable viral RNA or bacterial DNA in children with active recent-onset juvenile dermatomyositis (DM).
METHODS: Magnetic resonance imaging-directed muscle biopsies were performed in 20 children with active, untreated, recent-onset juvenile DM and in age-matched children with neurologic disease. Sera were tested for complement-fixing antibody to Coxsackievirus B (CVB), influenza A and B, parainfluenza 1 and 3, Mycoplasma pneumoniae, mumps, respiratory syncytial virus, and Reovirus; and by immunofluorescence for IgG antibody to Toxoplasma gondii cytomegalovirus and IgM antibody to Epstein-Barr virus. Muscle from juvenile DM patients and control children, CD-1 Swiss mice with and without CVB1 infection, and viral stock positive for CVB1-6 were tested using reverse-transcriptase polymerase chain reaction with 5 primer sets, 4 probes (1 Coxsackievirus, 3 Enterovirus), and universal primers for DNA.
RESULTS: No increased antibody, viral RNA, or bacterial DNA was present in the juvenile DM patients or the control children.
CONCLUSION: Juvenile DM may be triggered by unidentified agent(s) in the genetically susceptible host.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7575702     DOI: 10.1002/art.1780381019

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  8 in total

Review 1.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

Review 2.  The heterogeneity of juvenile myositis.

Authors:  Lisa G Rider
Journal:  Autoimmun Rev       Date:  2006-09-05       Impact factor: 9.754

Review 3.  Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment.

Authors:  Lucy R Wedderburn; Lisa G Rider
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-10       Impact factor: 4.098

4.  Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy.

Authors:  Timothy B Niewold; Silvia N Kariuki; Gabrielle A Morgan; Sheela Shrestha; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2009-06

5.  Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis.

Authors:  Stéphanie Christen-Zaech; Roopa Seshadri; Joyce Sundberg; Amy S Paller; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2008-02

Review 6.  Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms.

Authors:  Ilaria Pagnini; Antonio Vitale; Carlo Selmi; Rolando Cimaz; Luca Cantarini
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 10.817

Review 7.  Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools.

Authors:  Judith Wienke; Claire T Deakin; Lucy R Wedderburn; Femke van Wijk; Annet van Royen-Kerkhof
Journal:  Front Immunol       Date:  2018-12-18       Impact factor: 7.561

8.  Dermatomyositis and malignancy of the pharynx in Caucasian patients: report of two observations.

Authors:  C Botsios; P Ostuni; P Boscolo-Rizzo; M C Da Mosto; Leonardo Punzi; C Marchiori
Journal:  Rheumatol Int       Date:  2003-06-28       Impact factor: 3.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.